Appraisal of the burden of genital warts from a healthcare and individual patient perspective

Public Health

Volumn 125, Issue 7, 2011, Pages 464-475

  Scarbrough Lefebvre, C D ^a   Van Kriekinge, G ^b   Goncalves M A ^b   de Sanjose, S ^c,d  

^a Independent Consultant   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d Consorcio de Investigacin Biomdica de Epidemiologay Salud Pxblica ^*  (Spain)

Author keywords

Cost; Epidemiology; Genital warts; Incidence; Prevalence; Quality of life

Indexed keywords

DISEASE INCIDENCE; DISEASE PREVALENCE; DISEASE TREATMENT; EPIDEMIOLOGY; HEALTH CARE; INFECTIOUS DISEASE; QUALITY OF LIFE; SEXUALLY TRANSMITTED DISEASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ASSESSMENT; CONDYLOMA ACUMINATUM; COST OF ILLNESS; EARLY INTERVENTION; FEMALE; FRANCE; HEALTH CARE FINANCING; HEALTH CARE PRACTICE; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PRESCHOOL CHILD; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; RECURRENT INFECTION; REIMBURSEMENT; REMISSION; SEX DIFFERENCE; SOCIAL STATUS; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES;

CONDYLOMATA ACUMINATA; COST OF ILLNESS; FEMALE; FRANCE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; PREVALENCE; QUALITY OF LIFE; UNITED STATES;

FRANCE; UNITED KINGDOM; UNITED STATES;

HUMAN PAPILLOMAVIRUS;

EID: 79960396938     PISSN: 00333506     EISSN: 14765616     Source Type: Journal    
DOI: 10.1016/j.puhe.2011.01.016     Document Type: Article

References (111)

1. Kjaer S.K., Tran T.N., Sparen P., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007, 196:1447-1454.
2. Anorlu R.I. What is the significance of the HPV epidemic?. Can J Urol 2008, 15:3860-3865.
3. Moscicki A.B. Impact of HPV infection in adolescent populations. J Adolesc Health 2005, 37:S3-S9.
4. Hagensee M.E. Infection with human papillomavirus: update on epidemiology, diagnosis, and treatment. Curr Infect Dis Rep 2000, 2:18-24.
5. Koutsky L.A., Galloway D.A., Holmes K.K. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988, 10:122-163.
6. UK Collaborative Group for HIV and STI Surveillance Testing times. HIV and other sexually transmitted infections in the United Kingdom 2007, Health Protection Agency, Centre for Infections, London, Available from:, [last accessed 15.11.2009]. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1203496897276.
7. de Villiers E.M., Fauquet C., Broker T.R., et al. Classification of papillomaviruses. Virology 2004, 324:17-27.
8. Wiley D., Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006, 61(Suppl. 1):S3-14.
9. Bouvard V., Baan R., Straif K., et al. A review of human carcinogens - part B: biological agents. Lancet Oncol 2009, 10:321-322.
10. Hull S.C., Caplan A.L. Genital warts: mountains or molehills?. Lancet Infect Dis 2008, 8:277-278.
11. Dunne E.F., Markowitz L.E. Genital human papillomavirus infection. Clin Infect Dis 2006, 43:624-629.
12. Aubin F., Pretet J.L., Jacquard A.C., et al. Human papillomavirus genotype distribution in external acuminata condylomata: a large French national study (EDiTH IV). Clin Infect Dis 2008, 47:610-615.
13. Garland S.M., Steben M., Sings H.L., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199:805-814.
14. Vandepapeliere P., Barrasso R., Meijer C.J., et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005, 192:2099-2107.
15. Wang H., Qiao Y.L. Human papillomavirus type-distribution in condylomata acuminata of mainland China: a meta-analysis. Int J STD AIDS 2008, 19:680-684.
16. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007, 90:1-636.
17. Singer A., Monaghan J.M., Quek S.C. Lower genital tract precancer: colposcopy, pathology and treatment 2000, Wiley-Blackwell Publishing, Hoboken, NJ. 2nd ed.
18. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997, 102:3-8.
19. Revzina N.V., Diclemente R.J. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS 2005, 16:528-537.
20. Hariri S., Dunne E.F., Sternberg M., et al. Seroepidemiology of human papillomavirus type 11 in the United States: results from the third National Health and Nutrition Examination Survey, 1991-1994. Sex Transm Dis 2008, 35:298-303.
21. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819.
22. Manhart L.E., Holmes K.K., Koutsky L.A., et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis 2006, 33:502-508.
23. Bauer H.M., Ting Y., Greer C.E., et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991, 265:472-477.
24. Evander M., Edlund K., Gustafsson A., et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 1995, 171:1026-1030.
25. Rohan T., Mann V., McLaughlin J., et al. PCR-detected genital papillomavirus infection: prevalence and association with risk factors for cervical cancer. Int J Cancer 1991, 49:856-860.
26. Baldwin S.B., Wallace D.R., Papenfuss M.R., et al. Human papillomavirus infection in men attending a sexually transmitted disease clinic. J Infect Dis 2003, 187:1064-1070.
27. Herrero R., Castle P.E., Schiffman M., et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005, 191:1796-1807.
28. Partridge J.M., Hughes J.P., Feng Q., et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007, 196:1128-1136.
29. Richardson H., Kelsall G., Tellier P., et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003, 12:485-490.
30. Koshiol J.E., Laurent S.A., Pimenta J.M. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004, 31:748-752.
31. Markowitz L.E., Dunne E.F., Saraiya M., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56:1-24.
32. Wiley D.J., Douglas J., Beutner K., et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002, 35(Suppl. 2):S210-S224.
33. Franco E.L., Villa L.L., Sobrinho J.P., et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999, 180:1415-1423.
34. Trottier H., Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine 2006, 24(Suppl. 1):S1-15.
35. Giuliano A.R., Harris R., Sedjo R.L., et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis 2002, 186:462-469.
36. Moscicki A.B., Shiboski S., Broering J., et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998, 132:277-284.
37. Lacey C.J., Lowndes C.M., Shah K.V. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24(Suppl. 3):S35-S41.
38. Oriel J.D. Natural history of genital warts. Br J Vener Dis 1971, 47:1-13.
39. Winer R.L., Lee S.K., Hughes J.P., et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157:218-226.
40. Winer R.L., Kiviat N.B., Hughes J.P., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005, 191:731-738.
41. Beutner K.R., Reitano M.V., Richwald G.A., et al. External genital warts: report of the American Medical Association Consensus Conference. AMA expert panel on external genital warts. Clin Infect Dis 1998, 27:796-806.
42. Lacey C.J. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005, 32(Suppl. 1):S82-S90.
43. Beutner K.R., Wiley D.J., Douglas J.M., et al. Genital warts and their treatment. Clin Infect Dis 1999, 28(Suppl. 1):S37-S56.
44. Handley J.M., Maw R.D., Lawther H., et al. Human papillomavirus DNA detection in primary anogenital warts and cervical low-grade intraepithelial neoplasias in adults by in situ hybridization. Sex Transm Dis 1992, 19:225-229.
45. Holmberg S.D., Buchbinder S.P., Conley L.J., et al. The spectrum of medical conditions and symptoms before acquired immunodeficiency syndrome in homosexual and bisexual men infected with the human immunodeficiency virus. Am J Epidemiol 1995, 141:395-404. discussion 405-406.
46. Minkoff H.L., Eisenberger-Matityahu D., Feldman J., et al. Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus. Am J Obstet Gynecol 1999, 180:824-836.
47. Silverberg M.J., Ahdieh L., Munoz A., et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002, 29:427-435.
48. Wiley D.J., Harper D.M., Elashoff D., et al. How condom use, number of receptive anal intercourse partners and history of external genital warts predict risk for external anal warts. Int J STD AIDS 2005, 16:203-211.
49. Dinh T.H., Sternberg M., Dunne E.F., et al. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis 2008, 35:357-360.
50. Khan A., Hussain R., Schofield M. Correlates of sexually transmitted infections in young Australian women. Int J STD AIDS 2005, 16:482-487.
51. Munk C., Svare E.I., Poll P., et al. History of genital warts in 10,838 women 20 to 29 years of age from the general population. Risk factors and association with Papanicolaou smear history. Sex Transm Dis 1997, 24:567-572.
52. Klavs I., Grgic-Vitek M. The burden of genital warts in Slovenia: results from a national probability sample survey. Euro Surveill 2008, 13. pii:19032.
53. Hippelainen M., Syrjanen S., Hippelainen M., et al. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis 1993, 20:321-328.
54. Van Den Eeden S.K., Habel L.A., Sherman K.J., et al. Risk factors for incident and recurrent condylomata acuminata among men. A population-based study. Sex Transm Dis 1998, 25:278-284.
55. Lukasiewicz E., Aractingi S., Flahault A. Incidence and management of condylomata acuminata by French general physicians. Ann Dermatol Venereol 2002, 129:991-996.
56. Monsonego J., Breugelmans J.G., Bouee S., et al. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France. Gynecol Obstet Fertil 2007, 35:107-113.
57. Insinga R.P., Dasbach E.J., Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003, 36:1397-1403.
58. Chuang T.Y., Perry H.O., Kurland L.T., et al. Condyloma acuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features. Arch Dermatol 1984, 120:469-475.
59. Schofield M.J., Minichiello V., Mishra G.D., et al. Sexually transmitted infections and use of sexual health services among young Australian women: Women's Health Australia study. Int J STD AIDS 2000, 11:313-323.
60. Goncalves M.A., Burattini M.N., Donadi E.A., et al. Risk factors associated with genital warts in HIV-positive Brazilian women. Tumori 2003, 89:9-15.
61. Che Y.M., Wang J.B., Liu Y.H. Correlation between deoxyribonucleic acid loads of human papillomavirus and recurrence of condylomata acuminata. Int J STD AIDS 2005, 16:605-607.
62. De Marco F., Di Carlo A., Poggiali F., et al. Detection of HPV in genital condylomata: correlation between viral load and clinical outcome. J Exp Clin Cancer Res 2001, 20:377-383.
63. Clinical Effectiveness Group British Association for Sexual Health and HIV (BASHH). United Kingdom national guideline for the management of anogenital warts 2007, British Association for Sexual Health and HIV, London, Available from:, [last accessed 15.11.2009]. http://www.guideline.gov/summary/summary.aspx%3Fdoc_id%3D11605.
64. von Krogh G., Lacey C.J., Gross G., et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000, 76:162-168.
65. Williams P., von Krogh G. The cost-effectiveness of patient-applied treatments for anogenital warts. Int J STD AIDS 2003, 14:228-234.
66. Workowski K.A., Berman S.M. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2006, 55:1-94.
67. Alam M., Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol 2001, 137:337-341.
68. Edwards L., Ferenczy A., Eron L., et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human papillomavirus. Arch Dermatol 1998, 134:25-30.
69. Fox P.A., Tung M.Y. Human papillomavirus: burden of illness and treatment cost considerations. Am J Clin Dermatol 2005, 6:365-381.
70. Kennedy C.M., Boardman L.A. New approaches to external genital warts and vulvar intraepithelial neoplasia. Clin Obstet Gynecol 2008, 51:518-526.
71. Lacey C.J., Goodall R.L., Tennvall G.R., et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003, 79:270-275.
72. Langley P.C., Richwald G.A., Smith M.H. Modeling the impact of treatment options in genital warts: patient-applied versus physician-administered therapies. Clin Ther 1999, 21:2143-2155.
73. Langley P.C., Tyring S.K., Smith M.H. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manag Care 1999, 5:69-77.
74. Mayeaux E.J., Dunton C. Modern management of external genital warts. J Low Genit Tract Dis 2008, 12:185-192.
75. Merck & Co., Inc. Gardasil: full prescribing information 2009, Merck & Co., Inc, Whitehouse Station, NJ, Available from:, [last accessed 15.11.2009]. http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf.
76. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis; in press.
77. Price indices (MEI) 2009, Organisation for Economic Co-operation and Development, Paris, Available from:, [last accessed 15.11.2010]. http://stats.oecd.org/Index.aspx%3FDataSetCode%3DCSP2010.
78. OANDA Currency Converter. Historical exchange rates; 2009. Available from: [last accessed 16.11.2010]. http://www.oanda.com/currency/historical-rates.
79. UK Collaborative Group for HIV and STI Surveillance All new STI episodes seen at GUM clinics in the UK. Number of new STI episodes seen at genitourinary medicine clinics by sex, 1999-2008 2009, Health Protection Agency, Centre for Infections, London, Available from:, [last accessed 15.11.2009]. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1215589015024.
80. Simms I., Fleming D.M., Lowndes C.M., et al. Surveillance of sexually transmitted diseases in general practice: a description of trends in the Royal College of General Practitioners Weekly Returns Service between 1994 and 2001. Int J STD AIDS 2006, 17:693-698.
81. Centers for Disease Control and Prevention Sexually transmitted disease surveillance. Table 42: selected STDs and complications - initial visits to physicians' offices, national disease and therapeutic index: United States, 1966-2007 2007, US Department of Health and Human Services, Atlanta, GA, Available from:, [last accessed 15.11.2009]. http://www.cdc.gov/std/stats07/tables/42.htm.
82. Fleischer A.B., Parrish C.A., Glenn R., et al. Condylomata acuminata (genital warts): patient demographics and treating physicians. Sex Transm Dis 2001, 28:643-647.
83. Brown R.E., Breugelmans J.G., Theodoratou D., et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006, 22:663-670.
84. Taylor C.A., Keller M.L., Egan J.J. Advice from affected persons about living with human papillomavirus infection. Image J Nurs Sch 1997, 29:27-32.
85. Maw R.D., Reitano M., Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998, 9:571-578.
86. Voog E., Lowhagen G.B. Follow-up of men with genital papilloma virus infection. Psychosexual aspects. Acta Derm Venereol 1992, 72:185-186.
87. Conaglen H.M., Hughes R., Conaglen J.V., et al. A prospective study of the psychological impact on patients of first diagnosis of human papillomavirus. Int J STD AIDS 2001, 12:651-658.
88. Ireland J.A., Reid M., Powell R., et al. The role of illness perceptions: psychological distress and treatment-seeking delay in patients with genital warts. Int J STD AIDS 2005, 16:667-670.
89. Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analogue scales versus time trade-off elicitation. Proceedings of the 21st International papillomavirus conference, 390, Mexico City, Mexico; 2004.
90. Badia X., Colombo J.A., Lara N., et al. Combination of qualitative and quantitative methods for developing a new health related quality of life measure for patients with anogenital warts. Health Qual Life Outcomes 2005, 3:24.
91. Brisson M., Van de Velde N., De Wals P., et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007, 25:5399-5408.
92. Dasbach E., Insinga R., Elbasha E. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008, 115:947-956.
93. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13:28-41.
94. Kulasingam S.L., Benard S., Barnabas R.V., et al. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008, 6:4.
95. Szucs T.D., Largeron N., Dedes K.J., et al. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008, 24:1473-1483.
96. Woodhall S., Ramsey T., Cai C., et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008, 84:161-166.
97. Vilata J.J., Varela J.A., Olmos L., et al. Validation and clinical use of the CECA, a disease-specific quality of life questionnaire for patients with anogenital condylomata acuminata. Acta Derm Venereol 2008, 88:257-262.
98. Langley P.C., White D.J., Drake S.M. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004, 15:501-508.
99. Insinga R.P., Dasbach E.J., Elbasha E.H. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005, 23:1107-1122.
100. Chesson H.W., Blandford J.M., Gift T.L., et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004, 36:11-19.
101. Pirotta M., Stein A.N., Conway E.L., et al. Genital warts incidence and healthcare resource utilisation in Australia. Sex Transm Infect 2010, 86:181-186.
102. The UK Collaborative Group for HIV and STI Surveillance Trends in genital warts and genital herpes diagnoses in the United Kingdom. Health protection report 2007, vol. 1. Number 35, Health Protection Agency, Centre for Infections, London, Available from:, [last accessed 15.11.2009]. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1203084376408.
103. Trottier H., Franco E.L. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care 2006, 12:S462-S472.
104. Becker T.M., Stone K.M., Alexander E.R. Genital human papillomavirus infection. A growing concern. Obstet Gynecol Clin North Am 1987, 14:389-396.
105. Simms I., Fairley C.K. Epidemiology of genital warts in England and Wales: 1971 to 1994. Genitourin Med 1997, 73:365-367.
106. Fenton K.A., Lowndes C.M. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Transm Infect 2004, 80:255-263.
107. UK Collaborative Group for HIV and STI Surveillance Continued increase in sexually transmitted infections: an analysis of data from UK genitourinary medicine clinics up to 2007 2008, Health Protection Agency, Centre for Infections, London, Available from:, [last accessed 15.11.2009]. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1216022446179.
108. UK Collaborative Group for HIV and STI Surveillance Selected STI diagnoses made at GUM clinics in the UK: 1999-2008 2009, Health Protection Agency, Centre for Infections, London, Available from:, [last accessed 15.11.2009]. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1215589014053.
109. Centers for Disease Control and Prevention Sexually transmitted disease surveillance 2007, US Department of Health and Human Services, Atlanta, GA, Available from:, [last accessed 15.11.2009]. http://www.cdc.gov/std/stats07/Surv2007FINAL.pdf.
110. Chandler M.G. Genital warts: a study of patient anxiety and information needs. Br J Nurs 1996, 5:174-179.
111. Filiberti A., Tamburini M., Stefanon B., et al. Psychological aspects of genital human papillomavirus infection: a preliminary report. J Psychosom Obstet Gynaecol 1993, 14:145-152.